Archives for: April 28th, 2017

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million

Written by Josh Drumm, Ph.D. on April 28, 2017

Bedminster, NJ – April 28, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Announces $10 Million Underwritten Public Offering

Written by Josh Drumm, Ph.D. on April 27, 2017

Bedminster, NJ – April 27, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports Update on Neutrolin® Phase 3 LOCK-IT 100 Clinical Trial

Written by Josh Drumm, Ph.D. on April 20, 2017

Bedminster, NJ – April 20, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin®

Written by Josh Drumm, Ph.D. on April 12, 2017

Bedminster, NJ – April 12th, 2017 – CorMedix Inc. (NYSE…